4.4 Article

Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues

期刊

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2020.4342

关键词

E2F transcription factor 1; hepatocellular carcinoma; tissue microarray

资金

  1. Fund of National Natural Science Foundation of China [NSFC 81860717]
  2. Natural Science Foundation of Guangxi, China [2019GXNSFAA245074, 2019GXNSFAA245087, 2017GXNSFAA198017]
  3. Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi [2018KY0123]
  4. Guangxi Zhuang Autonomous Region Health Committee Self-Financed Scientific Research Project [Z20190529]
  5. Guangxi Medical University Training Program for Distinguished Young Scholars
  6. Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University
  7. Guangxi Degree and Postgraduate Education Reform and Development Research Projects, China [JGY2019050]
  8. Guangxi Higher Education Undergraduate Teaching Reform Project [2020JGA146]
  9. Guangxi Medical University Education and Teaching Reform Project [2019XJGZ04]
  10. Guangxi Medical University 2020 Undergraduate Innovation and Entrepreneurship Training Program [202010598002]
  11. Guangxi Medical University [WLXSZX20088]

向作者/读者索取更多资源

The study confirmed the upregulation of E2F1 in hepatocellular carcinoma (HCC) patients, with elevated E2F1 level correlating with Asian race, tumor classification, neoplasm histologic grade, eastern cancer oncology group, and plasma AFP levels. E2F1 possessed moderate discriminatory capability in differentiating HCC patients from non-HCC controls. Furthermore, two putative targeted genes (CCNE1 and CCNA2) of E2F1 were identified for their potential roles in regulating cell cycle and promoting antiapoptotic activity in HCC patients.
Background: To date, the clinical management of advanced hepatocellular carcinoma (HCC) patients remains tough and the mechanisms of E2F transcription factor 1 (E2F1) underlying HCC are obscure. Materials and Methods: Our study integrated datasets mined from several public databases to comprehensively understand the deregulated expression status of E2F1. Tissue microarrays and immunohistochemistry staining was used to validate E2F1 expression level. The prognostic value of E2F1 was assessed. In-depth subgroup analyses were implemented to compare the differentially expressed levels of E2F1 in HCC patients with various tumor stages. Functional enrichments were used to address the predominant targets of E2F1 and shedding light on their potential roles in HCC. Results: We confirmed the elevated expression of E2F1 in HCC. Subgroup analyses indicated that elevated E2F1 level was independent of various stages in HCC. E2F1 possessed moderate discriminatory capability in differentiating HCC patients from non-HCC controls. Elevated E2F1 correlated with Asian race, tumor classification, neoplasm histologic grade, eastern cancer oncology group, and plasma AFP levels. Furthermore, high E2F1 correlated with poor survival condition and pooled HR signified E2F1 as a risk factor for HCC. Enrichment analysis of differentially expressed genes, coexpressed genes, and putative targets of E2F1 emphasized the importance of cell cycle pathway, where CCNE1 and CCNA2 served as hub genes. Conclusions: We confirmed the upregulation of E2F1 and explored the prognostic value of E2F1 in HCC patients. Two putative targeted genes (CCNE1 and CCNA2) of E2F1 were identified for their potential roles in regulating cell cycle and promote antiapoptotic activity in HCC patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据